CARVYKTI
Total Payments
$24.7M
Transactions
7,015
Doctors
2,564
Companies
7
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $8.9M | 4,773 | 2,280 |
| 2023 | $8.4M | 1,424 | 299 |
| 2022 | $7.4M | 806 | 117 |
| 2021 | $3,900 | 12 | 12 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $23.4M | 2,438 | 94.8% |
| Consulting Fee | $910,575 | 358 | 3.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $182,333 | 81 | 0.7% |
| Food and Beverage | $118,931 | 3,919 | 0.5% |
| Travel and Lodging | $53,473 | 183 | 0.2% |
| Grant | $12,000 | 1 | 0.0% |
| Space rental or facility fees (teaching hospital only) | $1,500 | 1 | 0.0% |
| Education | $874.48 | 34 | 0.0% |
Payments by Type
Research
$23.4M
2,438 transactions
General
$1.3M
4,577 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against BCMA in Subjects with Multiple Myeloma | Janssen Research & Development, LLC | $10.4M | 0 |
| A Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Release in Patients with Multiple Myeloma | Janssen Research & Development, LLC | $5.9M | 0 |
| A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) | Janssen Research & Development, LLC | $4.3M | 0 |
| A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy | Janssen Research & Development, LLC | $916,670 | 0 |
| 68284528MMY4002 | Janssen Research & Development, LLC | $835,744 | 0 |
| Phase II study of Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma (CAR-PRISM) | Janssen Research & Development, LLC | $417,182 | 0 |
| Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene autoleucel (cilta-cel) Out-of-Specification (OOS) in patients with Multiple Myeloma | Janssen Research & Development, LLC | $240,564 | 0 |
| 68284528MMY4007 | Janssen Research & Development, LLC | $186,875 | 0 |
| Ghobrial_Phase II study of Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma (CAR-PRISM) | Janssen Research & Development, LLC | $104,465 | 0 |
| A Prospective Analysis of Manufacturing Outcomes with Patient Factors from Multiple Myeloma Patients Scheduled to Receive Ciltacabtagene Autoleucel | Janssen Research & Development, LLC | $57,706 | 0 |
| A Prospective Multinational Study of Real Life Current Standards of Care in Patients with Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI IMiD and CD38 Monoclonal Antibody Treatment | Janssen Research & Development, LLC | $29,957 | 0 |
| EVA-28328-00 | Janssen Scientific Affairs, LLC | $14,875 | 1 |
| EVA-33464-01 | Janssen Global Services, LLC | $450.00 | 1 |
Top Doctors Receiving Payments for CARVYKTI
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Tampa, FL | $23.5M | 2,447 |
| , M.D | Medical Oncology | New York, NY | $64,743 | 19 |
| , M.D | Hematology & Oncology | Rochester, MN | $60,409 | 22 |
| , M.D | Medical Oncology | Buffalo, NY | $55,420 | 79 |
| , MD | Internal Medicine | Milwaukee, WI | $36,188 | 34 |
| , MD | Internal Medicine | Duarte, CA | $29,982 | 27 |
| , M.D., M.P.H.,F.A.C.P | Hematology & Oncology | Atlanta, GA | $29,045 | 11 |
| , M.D | Specialist | Atlanta, GA | $25,182 | 28 |
| , M.D | Medical Oncology | Boston, MA | $24,994 | 1 |
| , MD | Internal Medicine | Salt Lake City, UT | $20,558 | 24 |
| , M.D | Internal Medicine | Houston, TX | $19,616 | 15 |
| , M.D | Hematology & Oncology | Boston, MA | $19,568 | 6 |
| , MD | Internal Medicine | Charlotte, NC | $18,082 | 23 |
| , NP | Adult Health | New York, NY | $17,790 | 27 |
| , M.D | Specialist | Los Angeles, CA | $17,000 | 1 |
| , M.D., PH.D | Neurology | New York, NY | $14,989 | 11 |
| , M.D | Hematology | Philadelphia, PA | $14,285 | 7 |
| , M.D | Hematology | Scottsdale, AZ | $13,994 | 8 |
| , M.D | Medical Oncology | New Orleans, LA | $13,650 | 6 |
| , M.D | Hematology & Oncology | Boston, MA | $13,500 | 1 |
| , M.D | Hematology | Stanford, CA | $13,146 | 14 |
| , MD | Medical Oncology | Philadelphia, PA | $12,717 | 12 |
| , MD | Internal Medicine | Indianapolis, IN | $12,612 | 10 |
| , MD | Hematology & Oncology | New York, NY | $12,565 | 7 |
| , M.D | Hematology & Oncology | Tampa, FL | $12,562 | 10 |
Ad
Manufacturing Companies
- Janssen Research & Development, LLC $23.7M
- Janssen Biotech, Inc. $437,196
- Janssen Scientific Affairs, LLC $210,734
- Legend Biotech USA Inc. $187,393
- Janssen Global Services, LLC $88,086
- Johnson & Johnson Health Care Systems Inc. $7,654
- Janssen Pharmaceuticals, Inc $112.75
Product Information
- Type Drug
- Total Payments $24.7M
- Total Doctors 2,564
- Transactions 7,015
About CARVYKTI
CARVYKTI is a drug associated with $24.7M in payments to 2,564 healthcare providers, recorded across 7,015 transactions in the CMS Open Payments database. The primary manufacturer is Janssen Research & Development, LLC.
Payment data is available from 2021 to 2024. In 2024, $8.9M was paid across 4,773 transactions to 2,280 doctors.
The most common payment nature for CARVYKTI is "Unspecified" ($23.4M, 94.8% of total).
CARVYKTI is associated with 13 research studies, including "A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against BCMA in Subjects with Multiple Myeloma" ($10.4M).